Allianz SE Sells 7,520 Shares of Lantheus Holdings, Inc. $LNTH

Allianz SE lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 95.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 386 shares of the medical equipment provider’s stock after selling 7,520 shares during the period. Allianz SE’s holdings in Lantheus were worth $32,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in LNTH. Harbor Capital Advisors Inc. boosted its position in Lantheus by 24.7% during the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock worth $15,554,000 after purchasing an additional 37,691 shares during the period. Reinhart Partners LLC. raised its position in shares of Lantheus by 16.4% in the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after purchasing an additional 197,719 shares during the period. Swedbank AB lifted its stake in shares of Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock valued at $119,925,000 after buying an additional 121,500 shares in the last quarter. Strs Ohio bought a new position in Lantheus in the 1st quarter worth approximately $4,529,000. Finally, Select Equity Group L.P. boosted its holdings in Lantheus by 899.2% in the 1st quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock worth $9,842,000 after buying an additional 90,751 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent research reports. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. JMP Securities reduced their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. TD Cowen dropped their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Finally, B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Lantheus currently has an average rating of “Hold” and a consensus price target of $74.17.

Lantheus Stock Performance

Shares of LNTH opened at $53.01 on Friday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The company has a market cap of $3.52 billion, a PE ratio of 14.10 and a beta of 0.04. The stock has a 50-day moving average price of $53.90 and a 200-day moving average price of $67.02.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million for the quarter. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Corporate insiders own 2.00% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.